Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus

Alessandra Iscaro,Christian Jones,Neil Forbes,Amina Mughal,Faith Nutter Howard,Haider Al Janabi,Secil Demiral,Yvonne Perrie,Magnus Essand,Aleksandra Weglarz,Luis J Cruz,Claire E Lewis,Munitta Muthana

DOI: https://doi.org/10.1016/j.nano.2021.102506

Nanomedicine

Abstract:Oncolytic viruses (OVs) selectively replicate in and destroy cancer cells resulting in anti-tumor immunity. However, clinical use remains a challenge because of virus clearance upon intravenous delivery. OV packaging using a nanomedicine approach could overcome this. Here we encapsulate an oncolytic adenovirus (Ad[I/PPT-E1A]) into CCL2-coated liposomes in order to exploit recruitment of CCR2-expressing circulating monocytes into tumors. We demonstrate successful encapsulation of Ad[I/PPT-E1A] into CCL2-coated liposomes that were preferentially taken up by CCR2-expressing monocytes. No complex-related toxicities were observed following incubation with prostate tumor cells and the encapsulation did not affect virus oncolytic activity in vitro. Furthermore, intravenous administration of our nanomedicine resulted in a significant reduction in tumor size and pulmonary metastasis in prostate cancer-bearing mice whereby a 1000-fold less virus was needed compared to Ad[I/PPT-E1A] alone. Taken together our data provide an opportunity to target OVs via circulation to inaccessible tumors using liposome-assisted drug delivery.